Based in the Boston biotech and medtech hub, Elucid Bioimaging is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, vascuCAP, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Based in the Boston biotech and medtech hub, Elucid Bioimaging is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, vascuCAP, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.

Avalon AI builds Deep Learning-based Computer Aided Diagnosis tools to facilitate the detection of brain degenerative diseases like Alzheimer's and enable better patient stratification in clinical trials.

Avalon AI builds Deep Learning-based Computer Aided Diagnosis tools to facilitate the detection of brain degenerative diseases like Alzheimer's and enable better patient stratification in clinical trials.